BIM

115.2

+1.5%↑

SRT3

228.5

-0.65%↓

GXI

55.15

+2.89%↑

ICAD

20.98

-1.04%↓

BIM

115.2

+1.5%↑

SRT3

228.5

-0.65%↓

GXI

55.15

+2.89%↑

ICAD

20.98

-1.04%↓

BIM

115.2

+1.5%↑

SRT3

228.5

-0.65%↓

GXI

55.15

+2.89%↑

ICAD

20.98

-1.04%↓

BIM

115.2

+1.5%↑

SRT3

228.5

-0.65%↓

GXI

55.15

+2.89%↑

ICAD

20.98

-1.04%↓

BIM

115.2

+1.5%↑

SRT3

228.5

-0.65%↓

GXI

55.15

+2.89%↑

ICAD

20.98

-1.04%↓

Search

Valneva SE

Avatud

3.15 1.29

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

3.09

Max

3.22

Põhinäitajad

By Trading Economics

Sissetulek

-28M

-37M

Müük

7.1M

53M

Aktsiakasum

-0.25

Kasumimarginaal

-69.865

Töötajad

713

EBITDA

-19M

-26M

Soovitused

By TipRanks

Soovitused

Osta

12 kuu keskmine prognoos

+80.95% upside

Dividendid

By Dow Jones

Järgmine tulemuste avaldamine

7. mai 2025

Turustatistika

By TradingEconomics

Turukapital

-57M

520M

Eelmine avamishind

1.86

Eelmine sulgemishind

3.15

Tehniline skoor

By Trading Central

Kindlus

Bullish Evidence

Valneva SE Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

15. nov 2024, 10:28 UTC

Suurimad hinnamuutused turgudel

European Vaccine Makers Under Pressure After Trump Picks RFK Jr to Lead Health Department

3. sept 2024, 10:28 UTC

Tulu

Pfizer, Valneva Report Positive Lyme Disease Vaccine Candidate Data

15. nov 2024, 10:34 UTC

Market Talk

Vaccine Sector Sell-Off Looks Overdone -- Market Talk

3. sept 2024, 10:31 UTC

Market Talk

Valneva Shares Gain on Positive Vaccine News -- Market Talk

Võrdlus sarnastega

Hinnamuutus

Valneva SE Prognoos

Hinnasiht

By TipRanks

80.95% tõus

12 kuu keskmine prognoos

Keskmine 5.7 EUR  80.95%

Kõrge 8.1 EUR

Madal 3.3 EUR

Põhineb 2 Wall Streeti analüütiku instrumendi Valneva SE 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Osta

2 ratings

1

Osta

1

Hoia

0

Müü

Tehniline skoor

By Trading Central

3.002 / 3.194Toetus ja vastupanu

Lühikene perspektiiv

Bullish Evidence

Keskpikk perspektiiv

Weak Bullish Evidence

Pikk perspektiiv

Bullish Evidence

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest Valneva SE

Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera and/or heat-labile toxin producing enterotoxigenic Escherichia coli bacterium; IXCHIQ, a single-dose, live-attenuated vaccine for the prevention of disease caused by chikungunya virus; and VLA2001, an inactivated whole-virus COVID-19 vaccine. The company also develops VLA15, a vaccine candidate, which is in Phase III clinical trial against Borrelia, the bacterium that causes Lyme disease; VLA1553, a vaccine candidate, which is in Phase III clinical trial against the chikungunya virus; VLA1554, a vaccine candidate targeting human metapneumovirus; and VLA2112, a vaccine candidate to treat patients with epstein-barr virus. It sells its products in the United States, Canada, Germany, Austria, Nordics, the United Kingdom, France, rest of European countries, and internationally. Valneva SE has collaborations with Pfizer, Inc. to co-develop and commercialize its Lyme disease vaccine; and Instituto Butantan for the development, manufacturing, and marketing of single-shot chikungunya vaccine. The company was founded in 1998 and is based in Saint-Herblain, France.